Semaglutide and eye issues: what the clinical evidence actually shows

What the NAION research found, and its limits

In mid-2024, a retrospective cohort study drew widespread attention when it reported that people prescribed semaglutide (for either type 2 diabetes or weight management) were significantly more likely to be diagnosed with NAION than people on other treatments. NAION is an uncommon condition in which the blood supply to the optic nerve is suddenly interrupted, typically causing painless vision loss in one eye. The study, covered extensively in the medical press and flagged by regulators, involved several hundred cases across the two groups.

What the research cannot tell us is whether semaglutide caused those cases. Observational studies identify associations, not mechanisms. People taking semaglutide for obesity or diabetes already carry higher baseline rates of vascular risk factors (hypertension, sleep apnoea, metabolic syndrome) each of which independently raises NAION risk. Disentangling a medicine's effect from those underlying conditions requires longer, controlled prospective data that does not yet exist. Regulatory bodies including the MHRA and the European Medicines Agency have noted the signal is under active review, but neither has concluded that semaglutide directly causes NAION. The NHS guidance on semaglutide advises patients to contact a doctor urgently for any sudden changes in vision, the right precaution while evidence accumulates.

If you are already using semaglutide and are worried, one practical habit takes under a minute: cover each eye in turn and check whether your vision looks the same on both sides. Any difference in clarity, a dark patch, or dimming should prompt an urgent call to your GP or 111, not a wait-and-see approach.

Diabetic retinopathy: a separate, better-understood eye risk

For people who have type 2 diabetes, there is a distinct and longer-established concern: rapid blood-sugar reduction can temporarily worsen existing diabetic retinopathy. When glucose levels fall quickly (as semaglutide can produce) the blood vessels in the retina, already stressed by years of high glucose, can undergo changes that cause haemorrhages or swelling. This phenomenon is recorded in the product literature and informed prescribing practice for Ozempic (the diabetes formulation of semaglutide) from the outset.

Wegovy, the weight-management formulation, is predominantly prescribed to people without diabetes, so the retinopathy concern applies less directly. That said, a proportion of people seeking weight-loss treatment do have prediabetes or undiagnosed type 2 diabetes, and their prescribers need that information. It is one reason a thorough consultation (capturing your full medical history) matters before any GLP-1 treatment begins. At our clinic, every assessment is read by a GPhC-registered Independent Prescriber who reviews the complete picture, not a checklist produced by software.

If you have a known retinal condition or have been told by an ophthalmologist that your eyes need monitoring, disclose this before starting semaglutide. Your prescriber can liaise with your eye specialist and adjust the titration plan if appropriate.

What regulators are watching, and what to do now

The MHRA continues to review post-market data on GLP-1 medicines, including semaglutide's visual-side-effect profile. The Yellow Card scheme is one of the tools that feeds this surveillance: when patients or clinicians report suspected reactions, those reports build the dataset regulators use to detect patterns. If you experience any visual symptom on semaglutide (even something that resolves quickly) filing a Yellow Card report takes only a few minutes and contributes directly to the safety evidence base.

For broader context on how semaglutide behaves as a medicine, including its common gastrointestinal side-effect profile and the situations where extra caution is warranted, the semaglutide overview page covers this in full. If you have questions specifically about Wegovy, the Wegovy treatment page explains the licensed schedule and eligibility criteria. A wider look at physical symptoms people sometimes notice on Wegovy (including digestive changes and other unexpected effects) is available across the semaglutide issues section of this site.

For questions about eyesight concerns linked to Wegovy specifically, or other physical changes like menstrual changes or sleep disturbances some patients notice, those pages go into more detail. And if you are weighing up whether treatment is right for you, a free consultation with one of our prescribers is the clearest way to get answers that are specific to your history.